恒瑞医药：羟乙磺酸达尔西利片已向国家药监局递交上市前沟通交流申请

Core Viewpoint - Heng Rui Medicine (600276) announced that its self-developed Darsilixian Hydroxyethyl Sulfonate Tablets, in combination with endocrine therapy, achieved statistical significance in the primary endpoint during a Phase III clinical trial for hormone receptor-positive, HER2-negative female breast cancer [1] Group 1 - The Phase III clinical trial was a multicenter, randomized, double-blind study [1] - The results indicated that Darsilixian combined with endocrine therapy significantly reduced the risk of recurrence compared to placebo combined with endocrine therapy [1] - The treatment also improved the invasive disease-free survival (IDFS) of patients [1] Group 2 - The company has recently submitted a pre-market communication application to the National Medical Products Administration's Drug Review Center [1]